Last reviewed · How we verify
agalsidase
At a glance
| Generic name | agalsidase |
|---|---|
| Also known as | agalsidase beta; Fabrazyme, agalsidase alfa; Replagal |
| Sponsor | Amicus Therapeutics |
| Modality | Biologic |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
Approved indications
- Fabry's disease
Common side effects
- Infusion-associated reactions
- Upper respiratory tract infection
- Chills
- Pyrexia
- Headache
- Cough
- Paresthesia
- Fatigue
- Peripheral edema
- Dizziness
- Rash
- Abdominal pain
Serious adverse events
- Severe infusion-associated reactions
Key clinical trials
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease (PHASE3)
- Fabry Disease Registry & Pregnancy Sub-registry
- Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease (PHASE3)
- Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (NA)
- A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.
- A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR Study
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |